BIBLIOGRAPHY

Bryant BL: Argyria resulting from intranasal medication. Arch Otolaryngol 31:127-139, 1940.

Collosols - British Colloids Limited, JAMA 78:674-675, March 4,1922. p. 674.

"Collosols": an uncritical English endorsement JAMA Oct. 18, 1919, p. 1218.

Fung MC, Bowen DL: Silver Products for Medicinal Indications: Risk - Benefit Assessment Clinical Toxicology, 34(l), 119-126(1996).

Fung MC, Weintraub M, Bowen DL: Colloidal silver proteins marketed as health supplements (letter) JAMA 1995 Oct 18:274(15):1196-7.

Gaul LE, Staud AH: Seventy cases of generalized argyria following organic and colloidal silver medication, including biospectrometric analysis of ten cases. [AMA 104:1387-1390, 1935.

Goodman LS, Gilman A: The Pharmacological Basis of Therapeutics. 5th edition New York: MacMillan, 1975:930-931, 999-1000.

Harker JM, Hunter D: Occupational Argyria British J Derm & Syphil Nov. 1935 p. 441-455.

Hartman RJ: Colloid Chemistry lst edition, Baltimore, Mifflin, 1939.

Hill WR, Montgomery H: Argyria Arch Derm Syphil 1941;44:588-99.

Hill WR, Pillsbury DM: Argyria: The Pharmacology of Silver, Baltimore, Md. Williams & Wilkins Co, 1939.

Levine SA, Smith JA: Argyria confused with heart disease. N Eng J Med 226:682-684,1942.

Marshall CR Killoh GB: The Bactericidal Action of Collosols of Silver & Mecury British Med J. Jan. 16,1915, p. 102.

Puckner WA: Collosol preparations Report of the Council on Pharmacy and Chemistry. JAMA June 7, 1919, p. 1694.

Roe AL, Collosol argentum and its ophthalmic uses. British Med J. Jan. 16,1915, p. 104.

Stillians AW: Argyria. Arch Dermatol 35:67-77,1937.

US Department of Health & Human services: Agency for Toxic Substances & Disease Registry. Atlanta, Georgia, Public Health Statement, March 1992.